title: [Ednit effects on activity of renin-angiotensin-aldosterone system and renal function in hypertensive subjects with diabetes mellitus].
abstract: OBJECTIVE
  To evaluate effects of enalapril (ednit) therapy on activity and reactivity of renin-angiotensin-aldosteron system (RAAS) and renal function.
  
  
  METHODS
  Ednit was given in a dose 5-10 mg/day to 30 patients with mild or moderate arterial hypertension (AH) in combination with moderate or severe non-insulin-dependent diabetes mellitus (NIDDM) in compensation or subcompensation of carbohydrate metabolism.
  
  
  RESULTS
  Ednit lowered blood pressure after 6-7 days of treatment. Normal blood pressure was achieved on the treatment week 4-6. Antihypertensive effect of ednit resulted from a significant reduction in a total peripheral vascular resistance under unchanged cardiac output. Adequate hypoglycemic and antihypertensive therapy normalized carbohydrate metabolism. Renal elimination of nitrogen did not change much. Glomerular filtration rate in patients with hyper- and hypofiltration returned to normal. Proteinuria reduced, microalbuminuria was not registered. RAAS activity normalized.
  
  
  CONCLUSIONS
  Ednit has both high antihypertensive activity and marked renoprotective effect with minor influence on carbohydrate metabolism in AH patients with NIDDM.
authors.forename: B Ia
authors.initials: BIa
authors.lastname: Zonis
authors.forename: N I
authors.initials: NI
authors.lastname: Volkova
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Sokolov
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D050260:Carbohydrate Metabolism; D002302:Cardiac Output / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007004:Hypoglycemic Agents; D004656:Enalapril